|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wood SL, Pernemalm M, Crosbie PA and
Whetton AD: Molecular histology of lung cancer: From targets to
treatments. Cancer Treat Rev. 41:361–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tse JC and Kalluri R: Mechanisms of
metastasis: Epithelial-to-mesenchymal transition and contribution
of tumor microenvironment. J Cell Biochem. 101:816–829. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kudo-Saito C, Shirako H, Takeuchi T and
Kawakami Y: Cancer metastasis is accelerated through
immunosuppression during Snail-induced EMT of cancer cells. Cancer
cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim AY, Kwak JH, Je NK, Lee YH and Jung
YS: Epithelial-mesenchymal transition is associated with acquired
resistance to 5-fluorocuracil in HT-29 colon cancer cells. Toxicol
Res. 31:151–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang L, He A, Zhang Q and Tao C: miR-126
inhibits cell growth, invasion, and migration of osteosarcoma cells
by downregulating ADAM-9. Tumour Biol. 35:12645–12654. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu
T, Bai Y, Shen Y, Yuan W, Jing Q and Qin Y: Endothelial-specific
intron-derived miR-126 is down-regulated in human breast cancer and
targets both VEGFA and PIK3R2. Mol Cell Biochem. 351:157–164. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li XM, Wang AM, Zhang J and Yi H:
Down-regulation of miR-126 expression in colorectal cancer and its
clinical significance. Med Oncol. 28:1054–1057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo C, Sah JF, Beard L, Willson JK,
Markowitz SD and Guda K: The noncoding RNA, miR-126, suppresses the
growth of neoplastic cells by targeting phosphatidylinositol
3-kinase signaling and is frequently lost in colon cancers. Genes
Chromosomes Cancer. 47:939–946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Du YY, Lin YF, Chen YT, Yang L,
Wang HJ and Ma D: The cell growth suppressor, mir-126, targets
IRS-1. Biochem Biophys Res Commun. 377:136–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hamada S, Satoh K, Fujibuchi W, Hirota M,
Kanno A, Unno J, Masamune A, Kikuta K, Kume K and Shimosegawa T:
MiR-126 acts as a tumor suppressor in pancreatic cancer cells via
the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol.
15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu B, Peng XC, Zheng XL, Wang J and Qin
YW: MiR-126 restoration down-regulate VEGF and inhibit the growth
of lung cancer cell lines in vitro and in vivo. Lung cancer.
66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang J, Lan H, Huang X, Liu B and Tong Y:
MicroRNA-126 inhibits tumor cell growth and its expression level
correlates with poor survival in non-small cell lung cancer
patients. PLoS One. 7:e429782012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang X, Chen BB, Zhang MH and Wang XR:
MicroRNA-126 inhibits the proliferation of lung cancer cell line
A549. Asian Pac J Trop Med. 8:239–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crawford M, Brawner E, Batte K, Yu L,
Hunter MG, Otterson GA, Nuovo G, Marsh CB and Nana-Sinkam SP:
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma
cell lines. Biochem Biophys Res Commun. 373:607–612. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tiscornia G, Singer O and Verma IM: Design
and cloning of an shRNA into a lentiviral silencing vector: Version
A. CSH Protoc. 2008:pdb.prot50092008.PubMed/NCBI
|
|
26
|
Zhang A, Dong Z and Yang T: Prostaglandin
D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition
in MDCK cells. Am J Physiol Renal Physiol. 291:F1332–F1342. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martelli AM, Evangelisti C, Chiarini F and
McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling
network as a therapeutic target in acute myelogenous leukemia
patients. Oncotarget. 1:89–103. 2010.PubMed/NCBI
|
|
28
|
Lechman ER, Gentner B, Ng SW, Schoof EM,
van Galen P, Kennedy JA, Nucera S, Ciceri F, Kaufmann KB, Takayama
N, et al: miR-126 regulates distinct self-renewal outcomes in
normal and malignant hematopoietic stem cells. Cancer Cell.
29:214–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grille SJ, Bellacosa A, Upson J,
Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and
Larue L: The protein kinase Akt induces epithelial mesenchymal
transition and promotes enhanced motility and invasiveness of
squamous cell carcinoma lines. Cancer Res. 63:2172–2178.
2003.PubMed/NCBI
|
|
30
|
Nieto MA: The snail superfamily of
zinc-finger transcription factors. Nat Rev Mol Cell Biol.
3:155–166. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/Akt pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen XF, Zhang HJ, Wang HB, Zhu J, Zhou
WY, Zhang H, Zhao MC, Su JM, Gao W, Zhang L, et al: Transforming
growth factor-β1 induces epithelial-to-mesenchymal transition in
human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling
pathways. Mol Biol Rep. 39:3549–3556. 2012. View Article : Google Scholar : PubMed/NCBI
|
